Baili Tianheng announced that the phase III clinical trial of BL-B01D1 (EGFR×HER3-ADC) for recurrent or metastatic esophageal squamous cell carcinoma completed the enrollment of the first patient.The translation is provided by third-party software. The above content is for informational or ...
行业: 中药 作者: 朱国广 发布机构: 东吴证券 发布日期: 2025-01-19东吴证券 - 医药生物行业跟踪周报:海外创新药峰会国产成果丰硕,建议关注百利天恒、科伦博泰、百济神州等 声明:本站内容均收集整理于互联网,目的在于传递更多信息,并不代表本站及子...